| Ticker: CNBI | 10394 Pacific Center Court | |
| Exchange: NASDAQ-National Market | San Diego, California 92121 | |
| Industry: Manufacturing | (619) 450-9600 |
| Type of Shares: | Common Shares | Filing Date: | 7/18/96 | |
| U.S. Shares: | 1,600,000 | Offer Date: | 10/2/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $12.50 - $13.50 | |
| Primary Shares: | 1,600,000 | Offer Price: | $12.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.88 | |
| Offering Amount: | $20,800,000 | Selling: | $0.53 | |
| Expenses: | $750,000 | Reallowance: | $0.10 | |
| Shares Out After: | 4,856,905 |
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Dain Bosworth Incorporated | Co-manager | (612) 371-2711 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $26.97 | $16.57 | $13.08 | Assets: | $32.23 |
| Net Income: | $1.02 | $0.86 | $0.73 | Liabilities: | $14.07 |
| EPS: | $0.30 | $0.25 | Equity: | $18.16 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is engaged in the development, production, marketing and distribution of a broad array of products used worldwide in disease-related life sciences research at pharmaceutical and biotechnology companies. There is also research done at academic institutions and government laboratories. The company's products include biochemical and biological reagents, antibodies, assays and research kits which it sells principally through its general and specialty catalogs under its well-established brand names, including Calibiochem and Novabiochem. With over 7,00 products, the company offers scientists the convenience of obtaining from a single source both innovative and fundamental research products, many of which are instrumental to areas of research such as cancer, cardiovascular disease, Alzheimer's and AIDS. The company believes it has established a long-standing reputation in the life sciences research products market for product quality, product reliability, extensive technical service and strong customer support. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for repayment of all amounts outstanding under the company's bank credit facility, working capital, general corporate purposes and possible acquisitions. |
©1996 IPO Data Systems, Inc. - All rights reserved.